Lumira Ventures
Venture capitalToronto · Pre-Seed–Late Stage · 17 people tracked
Also known as LUMIRA CAPITAL INVESTMENT MANAGEMENT INC.
Investment thesis
Lumira Ventures backs mission-driven entrepreneurs building transformative life sciences companies. The firm focuses on developing and commercializing impactful products aimed at improving outcomes for patients, positioning itself as a leading North American life sciences investor.
Source: firm website, verified Aug 3, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 43 of 56 portfolio companiesBiotech ×33Medical Devices ×30Healthtech ×19Digital Health ×7Deep Tech ×6AI & Machine Learning ×3FemTech ×1
HQs:United States×19Canada×4United Kingdom×1
Investments · 56 tracked
founders shown can be your intro pathEdesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics to treat inflammatory and immune-related diseases, with a current focus on acute respiratory distress syndrome and other immune dysregulation conditions.
BiotechDeep TechMedical Devices
Zymeworks develops novel medicines for patients with difficult-to-treat diseases using proprietary platforms and in-house R&D capabilities.
BiotechDigital HealthMedical DevicesVancouver, US
HAIG FARRIS(Director)SHERMAINE TILLEY(Director)NOEL HALL(Director)Kenneth Galbraith(Director)inNICK BEDFORD(Director)GORDON NG(Executive Officer)
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.
BiotechDigital HealthHealthtechMedical DevicesSammamish, US
Kent Leyde(Executive Officer, Director, Promoter)Warren Douglas Sheffield(Executive Officer, Director, Promoter)
Board seatGerry Brunk· per SEC Form D
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical Devices
Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Glenn Batchelder(Director)James Cohen(Director)Albert Gianchetti(Executive Officer, Director)
BiotechAtlanta, US
H. Daniel Perez, M.D.(Director)Maxim Gorbachev(Director)Nicole Vitullo(Director)Eric Springman(Executive Officer)Sanjeev Ahuja, M.D.(Executive Officer)Gerry Brunk(Director)
Board seatGerry Brunk· per SEC Form D · $40M raise · filed Jun 2015
BiotechTewksbury, US
Paul LaViolette(Director)Kevin Gillis(Director)Gerald Brunk(Director)George J. Fazio(Executive Officer, Director)Dan B. Curtis(Executive Officer)David Celermajer(Director)
Board seatGerry Brunk· per SEC Form D · $34M raise · filed Sep 2015
Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.
HealthtechWashington, US
Richard Geoffrion(Executive Officer, Director)Gerry Brunk(Director)Takahide Koda(Director)Robert Henkin(Director)
Board seatGerry Brunk· per SEC Form D · $12.8M raise · filed Nov 2020
HealthtechWoodridge, US
Jonathan Jonas(Director)Harry Rowland(Executive Officer, Director)Raymond S. Barrett, Jr.(Director)Anthony I Nunez(Executive Officer, Director)Sam R. Leno(Director)Leslie A. Saxon(Director)
Board seatGerry Brunk· per SEC Form D
Company whose formation and launch the LifeSci team supported.
BiotechHealthtechSummit, US
Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Gregory Mayes(Executive Officer, Director, Promoter)Gerry Brunk(Director)Heath Lukatch(Director)Warren Lammert(Director)
Board seatGerry Brunk· per SEC Form D
Exact Imaging develops the ExactVu micro-ultrasound platform, a medical device that enables urologists to perform targeted prostate biopsies with high-resolution real-time visualization.
HealthtechMedical Devices
Board seatPeter van der Velden· per SEC Form D
Histosonics develops histotripsy technology, a non-invasive ultrasound-based treatment modality for physicians to use in clinical procedures.
Deep TechHealthtechMedical DevicesAnn Arbor, GB
Wen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Gerry Brunk(Director)Jim Adox(Director)Kadir Kadhiresan(Director)
Board seatGerry Brunk· per SEC Form D
BiotechVerdun
Stephen Nelson(Director)Adele Gulfo(Director)Ken d'Entremont(Executive Officer, Director)Roland Boivin(Executive Officer)Terri Shoemaker(Executive Officer)Peter van der Velden(Director)
Board seatPeter van der Velden· per SEC Form D · $400K raise · filed Mar 2020
BiotechBoston, US
Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)Dr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)
Board seatGerry Brunk· per SEC Form D · $35M raise · filed Oct 2022
SpectraWave develops imaging and physiology technologies for coronary care, combining deep optical coherence tomography, near-infrared spectroscopy, and wire-free FFR measurements on a single platform to support percutaneous coronary intervention planning in catheterization laboratories.
AI & Machine LearningHealthtechMedical DevicesBedford, US
Eman Namati(Executive Officer, Director)Eric Swanson(Director)Martin Seifert(Executive Officer, Director)Steven Hochberg(Director)Guillermo Tearney(Director)
BoardPaul LaViolette(Director)
Board seatGerry Brunk· per SEC Form D
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Alveolus Bio develops inhaled biotherapeutics using a proprietary platform to deliver engineered bacteria directly to the lungs for treating chronic lung diseases including idiopathic pulmonary fibrosis, bronchiectasis, and COPD.
BiotechDigital HealthMedical Devices
AmacaThera develops a tunable hydrogel drug-delivery platform for long-acting therapeutic administration across various clinical applications, including pain management, oncology, and post-surgical care.
BiotechMedical Devices
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)Steven James(Director)
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Executive Officer, Director)
BoardCorey . Goodman(Director)Jonathan Leff(Director)Raymond J. Kelleher(Director)
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.
Digital HealthHealthtechMedical Devices
Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Garheng Kong(Director)Rik Vandevenne(Director)Gust H. Bardy(Executive Officer, Director, Promoter)Alan Levy(Director)
Biotheryx discovers and develops targeted protein degrader drugs designed to treat cancer and inflammatory diseases.
BiotechMedical DevicesSan Diego, US
Kyle Chan, PhD(Executive Officer)David Stirling, PhD(Executive Officer, Director)Louis DeGennaro, PhD(Director)Lawrence Zaslow(Executive Officer, Director)Frank Mercurio, PhD(Executive Officer)
Bright Angel Therapeutics develops novel small molecule therapeutics for treating drug-resistant and life-threatening fungal infections using computational drug discovery and proprietary fungal-selective inhibitor technologies.
BiotechDeep TechMedical DevicesToronto, CA
Cardiac Dimensions develops the Carillon Mitral Contour System, an implantable device therapy for treating functional mitral regurgitation (FMR) in heart failure patients.
BiotechHealthtechMedical Devices
Congruence is a drug discovery company using protein dynamics, biophysics, machine learning, and computational chemistry to develop predictive models for disease correction.
AI & Machine LearningBiotech
BiotechCharlottesville, US
Kevin S Eisenfrats(Executive Officer, Director, Promoter)Iris Van Alderwerelt van Rosenburgh(Director)Martin J Emerson(Director)Gurdane Bhutani(Director)Tom Thorpe(Director)Michael King(Director)
COUR develops targeted therapies for autoimmune diseases using an antigen-specific platform technology designed to restore immune tolerance while preserving normal immune function.
BiotechHealthtechMedical Devices
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)
Damona Pharma develops therapies targeting cognitive deficits by using positive allosteric modulators to restore neural connections and improve brain cell communication.
BiotechHealthtechMedical Devices
BiotechGermantown, US
Vera Mumm(Executive Officer)John Mumm(Executive Officer, Director)Pavel Khrimian(Executive Officer, Director)Lu Han(Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)
Fusion Pharma develops targeted alpha therapeutics for cancer treatment using proprietary linker technology to connect alpha-emitting medical isotopes to cancer-targeting molecules, delivering lethal damage to tumor cells while minimizing toxicity to healthy tissues.
BiotechHealthtechMedical Devices
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Timothy Sullivan(Director)Peter Kolchinsky(Director)Mark A. Velleca(Executive Officer, Director)Glenn Muir(Director)Gregory Mossinghoff(Executive Officer)Seth Rudnick(Director)
Cytek Biosciences develops spectral flow cytometry instruments and reagents for cell analysis in cancer and cell biology research.
BiotechDeep TechMedical DevicesBellevue, US
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing Tegavivint, a targeted Wnt/β-catenin inhibitor for cancers with Wnt-driven mutations, primarily hepatocellular carcinoma and colorectal cancer.
BiotechMedical Devices
KisoJi Biotechnology discovers and develops antibody therapeutics targeting oncology and other diseases using a proprietary platform based on single domain antibodies and AI-enabled fingerprinting technology.
AI & Machine LearningBiotechMedical Devices
OpSens Medical develops sensor-guided medical devices, including fiber optic guidewires and hemodynamic monitoring systems, for use in interventional cardiology procedures.
Digital HealthMedical Devices
Puzzle Medical Devices develops a cardiac support device designed to improve heart and kidney function in heart failure patients through a minimally invasive 4Fr axillary approach, enabling patient mobility during treatment.
HealthtechMedical Devices
Specific Biologics develops Dualase, a genome editing platform for in vivo therapeutic applications.
BiotechDeep TechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2024
Disclosed stake · filed Jan 2023
Disclosed stake · filed Jan 2020
Disclosed stake · filed Sep 2019
Disclosed stake · filed Aug 2019
Disclosed stake · filed Jun 2019
Disclosed stake · filed Feb 2018
Disclosed stake · filed Apr 2017
8 insider ownership filings (Forms 3/4/5)
at enGene Holdings Inc. (ENGN), Edesa Biotech, Inc. (EDSA)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Lumira Ventures invest at?
- Lumira Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Lumira Ventures's typical check size?
- Lumira Ventures typically writes checks of $1M – $10M.
- What sectors does Lumira Ventures focus on?
- Lumira Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Lumira Ventures located?
- Lumira Ventures is headquartered in Toronto, CA.
Images
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.